公开(公告)号：US20200283430A1

公开(公告)日：2020-09-10

申请号：US16759660

申请日：2018-10-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joseph E. Carpenter ,  Matthias Broekema ,  Jianxin Feng ,  Chunjian Liu ,  Wei Wang ,  Ying Wang

IPC: C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D487/04 ,  C07D471/04 ,  C07D519/00

Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20190127362A1

公开(公告)日：2019-05-02

申请号：US16175910

申请日：2018-10-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joseph E. Carpenter ,  Yanting Huang ,  Ying Wang ,  Gang Wu

IPC: C07D417/14 ,  C07D413/14 ,  C07D491/107 ,  C07D487/04 ,  C07D471/04 ,  C07D413/08 ,  C07D487/10 ,  C07D491/113 ,  C07D491/20 ,  C07D513/04 ,  C07D417/12 ,  C07D263/32 ,  C07D413/12 ,  C07D401/14 ,  C07H15/26

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20210380578A1

公开(公告)日：2021-12-09

申请号：US16759782

申请日：2018-10-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joseph E. Carpenter ,  Jianxin Feng ,  Ji Jiang ,  Soong-Hoon Kim ,  Ying Wang ,  Gang Wu

IPC: C07D417/14 ,  C07D413/14 ,  C07D413/06 ,  C07D471/08 ,  C07D487/04 ,  C07D401/14 ,  C07D471/04 ,  C07D513/04

Abstract: The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US11078198B2

公开(公告)日：2021-08-03

申请号：US16175910

申请日：2018-10-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joseph E. Carpenter ,  Yanting Huang ,  Ying Wang ,  Gang Wu

IPC: C07D261/08 ,  C07D263/32 ,  C07D401/14 ,  C07D413/08 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D491/113 ,  C07D491/20 ,  C07D513/04 ,  A61K31/42 ,  A61K31/428 ,  A61K31/429 ,  C07H15/26

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US11370785B2

公开(公告)日：2022-06-28

申请号：US16759782

申请日：2018-10-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joseph E. Carpenter ,  Jianxin Feng ,  Ji Jiang ,  Soong-Hoon Kim ,  Ying Wang ,  Gang Wu

IPC: C07D417/14 ,  C07D401/14 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D513/04

Abstract: The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US11168079B2

公开(公告)日：2021-11-09

申请号：US16759660

申请日：2018-10-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joseph E. Carpenter ,  Matthias Broekema ,  Jianxin Feng ,  Chunjian Liu ,  Wei Wang ,  Ying Wang

IPC: C07D401/14 ,  A61K31/4545 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.